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The rising incidence of Tuberculosis (TB) in South Africa is closely linked to the 
rapid spread of HIV/AIDS that has occurred over the last two decades. 
Compared to other developing countries in this regard South Africa faces a co-
epidemic crisis which must be addressed if HIV/TB is to be fought successfully. 
It is no longer sufficient to focus on each disease separately while neglecting the 
issues arising from co-infection. When these two diseases intersect it creates 
serious problems for TB diagnosis and treatment that are not yet adequately 
dealt with in the existing treatment frameworks. Moreover, TB is the leading 
cause of death among AIDS sufferers. There is scope for a broader set of TB 
diagnostic tools to be prescribed, in particular an urgent need for cheap and 
accurate TB tests to replace the current 120-year-old sputum microscopy. New 
tests are becoming available but only for a limited group in the private sector. 
This paper begins by exploring the link between HIV and TB, the data reveals 
that a change in HIV prevalence is strongly correlated with a change in the 
incidence of TB. Two techniques are employed to investigate this. The result is 
an exceptionally high rate of co-infection in countries such as South Africa, 
where there is high HIV prevalence and high incidence of active and latent TB. 
The paper then considers why this HIV/TB overlap is such a serious problem for 
patients and health care workers beyond the problems caused by each disease 
separately. In conclusion, four broad solutions are examined which would help 






The HIV/AIDS epidemic in South Africa is undoubtedly one of the most 
pressing national concerns as it devastates a large portion of the adult 
population, with serious social and economic consequences. Since the first 
diagnosis in 1982 UNAIDS estimates suggest that over three million South 
Africans have died from AIDS and the country has a higher number of HIV-
infected individuals than any other. At the same time as this HIV crisis unfolds, 
the incidence of Tuberculosis (TB) is also steadily rising. Data from the 
National TB Control Programme (NTBCP) show that over the last five years TB 
case notification has increased by 81%, from 188,695 cases in 2001 to 341,165 
in 2006 (National Tuberculosis Policy Guidelines, 2007). A serious concern in 
this regard is the intersection of HIV and TB, and the extent to which HIV 
prevalence is driving TB incidence. The overlap of these „terrible twins‟ causes 
numerous problems for the diagnosis of TB and increasingly forces doctors to 
make clinical decisions on the basis of probability rather than relying on a 
definitive medical test (WHO, 2004b). Furthermore, serious treatment 
difficulties can arise such as the development of Immune Reconstitution 
Inflammatory Syndrome (IRIS) which can be fatal, and TB is the leading cause 
of death among those infected with HIV in South Africa (3). This paper explores 
the link between HIV and TB, examines the problems caused by co-infection, 
and then considers some interventions that could lead to positive change.  
 
 
The Link between HIV/AIDS and Tuberculosis 
 
The World Health Organisation (WHO) estimates that the annual worldwide 
incidence of TB is 139 per 100 000; in Africa this rises to 363; while in South 
Africa there are approximately 948 people per 100 000 diagnosed with TB 
(WHO, 2009). Table 1, below, gives an overview of the TB burden worldwide 
and includes a section on South Africa. The table is divided into the 6 WHO 
regions for which TB incidence and prevalence are reported; in addition the 
extent of co-infection (patients with TB and HIV) is shown in the “HIV 
Prevalence” column. Here again the South African figures are higher than 
average; 73% of patients who are infected with TB are co-infected with HIV. 
Given the extent of this overlap it is useful to explore whether a change in one of 
the diseases is associated with a change in the other. Understanding this link 
would certainly clarify some of the epidemiological problems facing countries 
like South Africa and thus provide help in responding to the co-epidemic. 
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1000s per 100,000 per 100,000 1000s %
African Region 792,378 363 150 3,766 38
American Region 909,820 32 17 348 11
Eastern Med. Region 555,064 105 47 772 3.5
European Region 889,278 49 21 456 9.8
S.E. Asian Region 1,745,394 181 81 4,881 4.6
Western Pacific Region 1,776,440 108 48 3,500 2.7
GLOBAL 6,668,374 139 61 13,723 15
SOUTH AFRICA 48,577 948 358 336 73
¹ Incidence is the number per 100 000 population per annum
Source: WHO 2009




The Physiological Link 
 
The physiological connection between HIV and TB is relatively straightforward 
and it is widely accepted that a change in HIV prevalence can easily precipitate 
a change in TB incidence within a given population (Corbett, Mallory, 
Churchyard, Kleinschmidt, De Cock, 2000; Swaminathan, Ramachandran, 
Baskaran, Paramasivan, Ramanathan, Venkatesan, Prabhakar & Datta, 2000). 
The rationale behind this theory is discussed below. 
 
TB is a bacterial disease, primarily transmitted through sputum particles in the 
air, therefore easily spread and contracted. Once infected with TB a healthy 
immune system is capable of fighting off the infection and successfully 
preventing the bacteria from multiplying (WHO, 2004b). Consequently, while 
the body remains infected with TB the disease is kept under control and the 
individual does not get sick – this individual is said to have latent TB (WHO, 
2004b). It is estimated that approximately 80% of South Africans have latent 
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 TB Incidence: this table gives the figures for two kinds of TB incidence - the first includes 
all forms of TB, pulmonary and extra pulmonary, diagnosed using the sputum smear 
microscopy as well as through x-rays, and other methods; while the second column, the 
“smear +ve”, indicates the incidence for patients who were diagnosed positively for TB 




 (Coetzee, Nachega, Adendorff, Msandiwa, Gray, Intyre & Chaisson, 2002). 
In contrast if the immune system is weak when the disease is contracted, or 
becomes weak with latent TB present in the body, the TB bacteria begin to 
multiply and this causes the infected person to become sick – this is called active 
TB, the extent of which was illustrated in Table 1 (WHO, 2004b). In the case of 
HIV infected individuals, the immune system can become very frail in the early 
and late stages of the disease, thereby rendering the individual more vulnerable 
to TB.  
 
HIV infection leads to progressive immunodeficiency and increased 
susceptibility to infections such as TB. HIV positive people are thus at high risk 
of infection and when their immune systems are weak the disease will not be 
suppressed. It is estimated by the WHO that on average there is a 50% chance of 
contracting TB if one is HIV positive compared to between a 5% and 10% 
chance if one is HIV negative (WHO, 2004b).  A previous study by Grange et al 
also asserts that the risk of developing TB if one is HIV positive is 20.6 times 
higher than if one is HIV negative (Grange, Henderson, Malon & Zumla, 2000). 
In countries where a large proportion of the population already have latent TB, 
such as South Africa, the problem is more acute and these odds may be even 
higher. The spread of HIV and consequent weakening of the immune system 
causes latent TB to become reactivated; therefore, as HIV spreads in a 
population with high rates of latent TB the extent of co-infection also increases. 
In addition, when active TB becomes more prevalent the problem is perpetuated 
because those with active TB easily infect others.  
 
 
What the data suggests 
 
The medical explanation of this link is well founded, widely accepted, and 
appears to be supported by the high percentage of co-infections in South Africa. 
However, it is useful to explore the empirical association between HIV and TB 
in more detail. Two approaches are used to investigate this: 
 
1.  Examining the HIV and TB data over time for South Africa and 
Uganda. Fitted curves are plotted using Spectrum
3
 to observe and 
compare the trends. 
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 A major factor contributing to the high rate of TB infections is the socio-economic 
conditions facing many South Africans, where living conditions are poor, crowded and thus 
relatively unhygienic. TB is more easily contracted and spread in such settings (7).  
3
 Spectrum is an epidemiological modelling tool which can be downloaded from 
hhtp://www.policyproject.com/software.cfm?page=Software&ID=Spectrum. 
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2.  Formulating a cross country regression to examine the effect of a 




Spectrum HIV/TB Curves 
 
Comparing trends in HIV prevalence and TB in Uganda and South Africa serves 
as a useful test of the relationship between these two diseases. If the medical 
explanation is correct, then the trends in TB cases should mirror trends in HIV 
cases. As Uganda‟s HIV epidemic peaked in the late 1990‟s, whereas South 
Africa‟s peaked a decade later, we should expect TB cases to have fallen in 
Uganda and risen in South Africa over the past decade in line with trends in HIV 
cases.  
 
Using Spectrum the HIV prevalence and TB incidence curves for each country 
were generated with data from the WHO and UNAIDS (WHOSIS, 2009; 
UNAIDS/WHO, 2008). The curves in Figure 1 show the HIV prevalence and 
TB incidence for South Africa from 1990-2009 and 1980-2009, respectively. 
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 „Incidence‟ reports the number of new cases of a disease per year, while „prevalence‟ gives 
the total number of people infected in a given population. Incidence is thus used to measure 
the extent of TB – because TB is curable so the patients who have it in one year may not have 
it the following year -; while Prevalence is used to measure the extent of HIV infection– given 
that once a patient is HIV positive they remain infected for life. 
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It is clear that the extent of both HIV and TB in South Africa has increased  
significantly over the past two decades with a correlation coefficient of 0.93. 
This suggests that the increasing HIV prevalence is closely linked to the rise in 
TB incidence. However, one must be careful to assume causation from 
correlation, or to rule out the effect of some external factor/s which may affect 
both diseases.  
 
The curves for Uganda from 1982-2007 are shown below. 
 






































The cubic nature of both curves is immediately clear. It can be seen in figure (a) 
that after rising steeply in the first half of 1990, by 1996 the number of people 
with HIV in Uganda begins to decline. After 1999 TB incidence also begins to 
fall
5
. This sheds more light on the relationship between the two diseases because 
we can see that in both countries the progression of TB follows that of HIV. 
This comparative evidence from South Africa and Uganda bolsters the medical 





Cross country regression analysis enables us to explore the link further. This 
regression explores the relationship between the change in HIV prevalence and 
the change in TB incidence over the period 1994 – 2007, controlling for relevant 
socio-economic variables. Data was obtained for 51 African countries from 
UNAIDS, the WHO and the World Bank (WHOSIS, 2009). All data for the 
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 The TB curve for Uganda shown in Figure 2(b) begins declining slightly earlier than the 
overall data suggests – around 1998 instead of after 2000. This has to do with the method 
Spectrum uses to calculate the incidence curve: inputs for the TB incidence with HIV and the 
incidence without HIV are required; one is thus forced to split up the total incidence into these 
categories. But while TB incidence without HIV continues to increase up until 2003 in 
Uganda, the incidence in people with HIV falls after 1998. It appears that for some reason 
Spectrum weights the latter more heavily than the former which produces the curve shown in 
Figure 2(b) where the decline begins just after 1998. The curve would otherwise have only 
begun to fall a few years later. 
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independent economic variables were for the year 2004. The general regression 
equation is formulated as follows: 
∆TB Incidence = C + β1(level of healthcare)  + β2(%urban population) + 
β3(life expectancy) + β4(GNI per capita) + β5(∆HIV prevalence) + ε. 
 
In short, this regression uses cross country data and observes to what extent 
changing HIV prevalence can “explain” changes in the TB incidence, while 
controlling for other aggregate socio-economic factors potentially linked to TB. 
It is important to keep this general aim in mind when reading the results, which 
are presented and discussed below. Table 2 presents the list of variables and the 
results of 3 multivariable OLS (Ordinary Least Squares) regression 
specifications. 
 
Table 2:  Cross Country Regression Analysis 
Dependent Variable:                               
Change in TB Incidence (1994-2007)
1 2 3
Change in HIV Prevalence (1994-2007) 26.082**  (4.202) 28.615**  (4.040) 33.316**  (4.035)
GNI per capita -0.007   (0.004) -0.001    (0.004) -0.004     (0.193)
Number of Physicians per 1000 people -26.997  (54.63) -39.22     (75.64)
% of the population that is urban 0.13161   (1.126) 0.6483   (1.150) 0.4288     (0.006)
Per Capita Health Expenditure -3.5142    (7.436) 
Life Expectancy -6.6053*  (2.396) -6.569   (2.369)
Constant 408.22    (119.8) 385.67   (97.76) 103.31     (43.32)
Number of Observations (N) 50 42 42
Adjusted R² 0.711 0.704 0.649
Coefficients are shown, with standard errors in parenthesis()
*5% significance 
**1% significance  
 
All three specifications report an adjusted R² of 65% or more.  Put differently, 
the independent variables explain at least 65% of the variation in TB incidence 
over time. No heteroscedasticity was present in the models
6
 and a correlation 
matrix is presented in the Appendix to show that there was no significant 
correlation between the independent variables. 
 
In comparing the models one can observe that Equation 1 has the highest R² and 
most number of significant variables. However, it suffers from the risk of a two-
way (endogenous) relationship between Health Expenditure and TB incidence in 
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 Results of White‟s test for heteroscedasticity are shown in the Appendix for equation 1; the 
result was the same for equations 2 and 3.  
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that higher levels of health expenditure may affect TB incidence, but TB 
incidence may also affect the level of health expenditure. This means that health 
expenditure may be correlated with other factors that explain TB incidence, 
which violates the OLS assumption of there being no relationship between the 
explanatory variables and the disturbance term (which inter alia picks up the 
effect of unmeasured variables). To overcome this problem Equation 2 uses a 
variable related to the level of healthcare in a country (which is what health 
expenditure is being used to capture) but not directly to health expenditure, 
namely the „number of physicians per 1000 people‟.  
 
In addition to omitting the health expenditure variable, Equation 3 omits „Life 
Expectancy‟ because it is also most likely influenced by both TB incidence and 
HIV prevalence. This equation has an adjusted R² of 0.65 and the four 
independent variables report results similar to Equations 1 and 2. As should be 
expected the coefficient of „HIV prevalence‟ increases when independent 
variables are dropped but it maintains a range of 26 to 33 over the three 
equations, which is a relatively large coefficient value in each case. The 
variables from equation 3 are explained and interpreted here. 
 
- GNI per capita. This variable is used as a broad measure of development 
given that other poverty measures are not readily available for many 
African countries. The coefficient of GNI per capita is negative (-.004), 
suggesting that poorer populations experience higher levels of TB 
incidence. While the sign is as expected, the variable is not statistically 
significant and the coefficient is small. 
- Physicians per 1000. Used instead of Health Expenditure this variable tries 
to capture the level of healthcare in each country and the effect of this on 
TB incidence. Although it solves the problem of endogeneity the data 
available on „physicians per 1000‟ is not available for all countries so the 
number of observations falls to 42. The adjusted R² is not negatively 
affected, as Equation 2 proves. The variable itself is not significant at the 
5% level and has an extremely high standard error, which may be due to 
the small sample size, but it does suggest that having more physicians is 
related to a small decrease in TB incidence, which is what one would 
expect.  
- Urban Population. Higher proportions of urban population are related to 
higher TB incidence. This may be because TB spreads more easily in areas 
where people live in close proximity to one another such as cities, 
particularly in crowded informal settlements which are a salient feature of 
most South African cities (WHO, 2009). But while the variable reflects this 
relationship with a positive coefficient of 0.42, it is statistically 
insignificant and the effect is fairly small.  
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- Change in HIV prevalence. Finally, and most importantly, the output shows 
that, controlling for the other variables, a positive change in HIV 
prevalence is linked to a positive change in TB incidence. The 
interpretation is that a 1% increase in HIV prevalence in Africa is 
associated with an increase in TB incidence of 33.3. This means that on 
average 33 more people out of 100,000 contract TB when HIV prevalence 
increases by 1%. The variable is significant at the 1% level and has a 
relatively small standard error; this is also the case in equations 2 and 3. 
 
The regression results, while facing certain data constraints, undoubtedly 
support the medical hypothesis regarding the link between HIV and TB given 
the strong positive co-efficient of “Change in HIV Prevalence”. This, together 
with the comparative time-series curves for South Africa and Uganda, and the 
medical argument, strongly suggests that changes in HIV prevalence can lead to 
changes in TB incidence. While this does not imply that in attempting to fight 
both diseases countries could simply focus all efforts on reducing HIV 
prevalence, it does suggest that progress against HIV/AIDS will result in lower 
rates of TB incidence. Accepting this link, the paper now turns to examine some 
of the major problems caused by HIV/TB co-infection, explaining why it is such 
a serious concern. 
 
 
The Problems of HIV/TB 
 
TB is the most common form of HIV-associated infection and the leading cause 
of AIDS-related death in South Africa (Corbett, Watt, Walker, Maher, Williams, 
Raviglione & Dye, 2003; Harries, Hargreaves, Kaluwa, Nyangulu & Salaniponi, 
2003). Ironically, HIV is easy to diagnose using accurate serological tests but 
there is no cure for the disease, while TB is curable using freely available anti-
tuberculosis treatment but it can be very difficult to diagnose – especially in 
HIV positive patients (Wilson, 2005). This section examines the problems 
caused by HIV/TB co-infection, particularly in diagnosis and treatment of TB. 
 
The most problematic cases for health workers are those where a patient is HIV 
positive and is suspected of having TB, but the TB cannot be accurately 
diagnosed. Increasingly in such cases health workers are forced to make 
treatment decisions on the basis of probability, instead of relying on the 
prescribed diagnostic tests required by the National TB Control Program 
(NTBCP) to place a patient on treatment (Wilson, 2005). Evidence from Table 1 
showed that in 2008 only 37% of the incident TB cases in South Africa were 
diagnosed positively using the prescribed Sputum Smear Microscopy Test.  
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TB is a disease most commonly contained in the lungs - this is known as 
pulmonary TB (PTB) (WHO, 2004b). But the disease can also be contained in 
other parts of the body such as the abdomen, bone marrow, or around the heart - 
this is known as extra pulmonary TB (EPTB) (WHO, 2004b). Pulmonary and 
extra pulmonary TB are diagnosed using different methods, with EPTB being 
harder to diagnose accurately (unfortunately EPTB is becoming more prevalent 
among HIV positive patients as the TB spreads easily in a weak immune 
system) (National Tuberculosis Policy Guidelines, 2007; WHO, 2004b).  
 
Currently there are several ways in which TB is diagnosed and healthcare 
workers have a brief window of opportunity in which to make a diagnostic 
decision before patients could become too ill to visit healthcare facilities 
(Corbett, Charalambous, Moloi, Fielding, Grant, Dye, De Cock, Hayes, 
Williams & Churchyard, 2004). Unlike TB in HIV negative patients, which is 
usually an indolent disease developing over months, HIV-associated TB is 
aggressive and can render immune-compromised patients moribund within 
weeks (Corbett, et al., 2004). In an HIV positive patient the presence of TB may 
also allow the HIV to multiply more quickly resulting in rapid progression of the 
virus (WHO, 2004b). This makes early diagnosis and treatment crucial. 
 
PTB in a relatively healthy immune system is diagnosable through a Sputum 
Smear Microscopy Test, where laboratory technicians use a microscope to 
identify Acid-Fast Bacilli (AFB) in the sputum (National Tuberculosis Policy 
Guidelines, 2007). This is the test recommended by the WHO and is required by 
the NTCP.  The South African TB guidelines stress: “…bacteriological 
confirmation of disease is the standard required for the diagnosis of pulmonary 
TB in adults.” (National Tuberculosis Policy Guidelines, 2007) It is 
approximately 60% accurate in testing HIV negative patients (WHO, 2004b). 
However, the rapid spread of HIV in South Africa has challenged this strategy 
and the data in Table 1 confirm this. HIV positive patients are far more likely to 
have extra pulmonary infection and, given their weakened immune systems, 
they are also less able to contain the TB bacteria within the lungs, which is 
essential for diagnosis using this test (Corbett, et al., 2004). The sputum smear 
has therefore become considerably less effective as an accurate test for TB in 
patients who are infected with HIV.  
 
Dr Laurel Giddy, director of the Knysna HIV and TB clinics affirms this, “The 
probability of TB increases as the CD4 count drops below 350, and increases 
exponentially as the CD4 drops below 100.  Any TB patient can be sputum 
negative if the sputum collection method is faulty.  However, many patients with 
CD4s fewer than 50 may be sputum negative as they don‟t have enough 
immunity to confine TB to their lungs and it becomes disseminated for example, 
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in other organs like the spleen, in lymph nodes, etc. These sites are less directly 
accessible, and this makes diagnosis more difficult” (Giddy, 2009).  
 
This leaves a large number of people with TB undiagnosed and untreated. 
Furthermore, the current treatment policy only allows a patient to be pronounced 
“cured” if they were initially sputum positive and become sputum negative after 
completing their treatment (National Tuberculosis Policy Guidelines, 2007). The 
smear positive cure rates are reported below and should be judged against the 
accepted WHO cure rate target of 85%.  
 
Table 3: South African TB Smear Positive Cure Rates7 
Year 2000 2001 2002 2003 2004 2005 2006
Cure Rates 54.0% 53.7% 54.1% 56.7% 50.8% 57.6% 62.9%  
Source: South African Department of Health, 2009 
 
Without the change from sputum positive to negative a patient cannot officially 
be said to be cured of TB and thus the current statistics on “cure rates” in Table 
3 only reflect the fraction of patients who are initially diagnosed as smear 
positive. Increased co-infection therefore makes it difficult to be sure of the total 
cure rates, especially since such a small percentage of TB infections in South 
Africa are diagnosed as smear positive. 
 
In addition to taking sputum smears from patients the NTCP recommends a 
chest radiograph (x-ray) if the first two smears are negative (National 
Tuberculosis Policy Guidelines, 2007). A third smear is suggested if the x-ray is 
suggestive of TB (National Tuberculosis Policy Guidelines, 2007). Following 
these guidelines TB can be diagnosed in many HIV-infected patients (Corbett, et 
al., 2004). However, the gold standard for diagnosing TB is through a 
mycrobacterial culture. This method accurately diagnosis over 80% of TB cases 
and is the only way to diagnose Multi-Drug Resistant TB (MDR-TB) (Corbett, 
et al., 2004). The reason it has not replaced the sputum smear for general 
diagnosis is that a culture can take up to 6 weeks to return results and is also 
prohibitively expensive (Iseman, 2000). While it is prescribed for patients who 
have had TB previously, many co-infected patients do not have such time to 
spare and may die before the results become available (Giddy, 2009). New 
diagnostic tools are slowly being discovered but as yet no cheap, accurate tests 
are available to the general population.  
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 Definition: The percentage of smear positive TB patients who are proven to be cured using 
sputum smear microscopy at the end of treatment.  
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In many cases doctors face a serious dilemma when seeing an HIV positive 
patient who is sick with possible TB; a typical scenario is described here in 
order to explain the problems more clearly.  
 
Following standard procedure a patient suspected of having TB will be tested 
using the sputum smear microscopy and a chest radiograph. If the tests confirm 
TB then a six month treatment regime follows for the patient and if they adhere 
to this they will be cured. However, assuming the smear returns negative, the x-
ray is inconclusive, and they cannot wait for a culture result, the doctor or nurse 
now faces a difficult choice. The physical symptoms may suggest that TB is 
present but the prescribed tests do not confirm this. There are thus three 
possibilities:  
- The tests failed to pick up the TB (as they are only 60% accurate),  
- The patient has some form of EPTB and further testing is necessary,  
- It may be that the physical symptoms are due to the HI-virus and an 
opportunistic infection such as pneumocystis carinii pneumonia 
(PCP), not TB.  
Either way, a decision must be made to place the patient on a full 6-month 
course of TB chemotherapy, or not. 
 
If the doctor decides not to treat for TB and the patient does in fact have TB it is 
almost certain that this patient will spread the disease to others and if the TB 
remains undiagnosed for long enough it may eventually result in death. Also, if 
we assume that the patient is HIV positive and gets put onto ART at some point 
with undiagnosed TB there is a risk that they may acquire Immune 
Reconstitution Inflammatory Syndrome, which can be fatal
8
 (Balakrishnan, 
Kumarasamy, Lloyd, Murugavel, Shankar, Sekar, Solomon & Vignesh, 2007). 
Dr Giddy, when questioned on how doctors make such decisions explains: “One 
has to be extremely careful when putting a patient on ARVs. Generally we err 
on the side of caution and give „unnecessary‟ TB treatment first, because TB 
IRIS untreated can be deadly.” (Giddy, 2009)  
 
If, as Dr Giddy suggests, the patient is treated for TB as a precaution but it turns 
out that no TB was present the patient suffers 6 months of unnecessary 
treatment, which is preferable given the risks but can have various side effects. 
These include liver and kidney toxicity, skin rashes, pill burden, and the delayed 
diagnosis of other causes of symptoms. If this treatment coincides with ART 
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 IRIS can occur when a patient is taking ART but has untreated TB. The ART begins to 
reconstitute the patient‟s immune system and as the immune system begins operating again it 
is able to recognise existing TB bacteria which it could not do when it was overwhelmed by 
the HI-virus. It then tries to fight the TB bacteria and in doing so the TB can overwhelm the 
already fragile immune system and cause the patient to die. 
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there are also possible drug interactions where the efficacy of the ART is 
compromised. Furthermore, the likelihood of the said patient defaulting on 
either treatment is higher, and if the patient does default on their TB medication 
then drug resistant strains of TB can develop and spread more easily (WHO, 
2004b). This scenario highlights the difficulties faced in diagnosis of TB and the 
need for development of a rapid, cost-effective diagnostic test.  
 
It is argued by activists that the reason doctors still use a 120-year-old TB test, 
and no new drugs have reached the market in 35 years, is because TB does not 
affect rich countries therefore drug companies see no profit in new TB research 
(Achmat & Roberts, 2005). Whether or not this is true it is surprising that 
satisfactory TB tests are not yet widely available. A Médicins Sans Frontiéres 
(MSF) poster captures this attitude toward the state of TB drugs and tests: it 
shows the picture of a young, solemn, female doctor and the print reads, “Don‟t 
tell me TB is under control. The TB drugs I‟m prescribing were invented before 
I was born. And we have to rely on a TB test that was developed 120 years ago.” 
(Equal Treatment, 2005) The fact that current tests and drugs are inadequate to 
deal with the co-infection epidemic is undeniable and highlighted by the 
numerous problems encountered. In general the consequences of co-infection 
include the following: 
• Over-diagnosis of sputum smear-negative TB (due to difficulties 
in diagnosis); 
• Under-diagnosis of sputum smear-positive TB (due to excess 
laboratory workload); 
• Inadequate supervision of anti-TB chemotherapy; 
• Low cure rates; 
• High mortality rates during treatment; 
• High default rates because of adverse drug reactions, high pill-
taking burden, and HIV dementia; 
• High rates of TB recurrence; 
• Increased transmission of drug-resistant TB strains among HIV-
infected patients. (WHO, 2004b) 
 
In addition to these issues the number of clinical visits which co-infected 
patients must make requires substantial absence from work which could become 
a growing problem for both employers and employees. The problems 
highlighted in this section are numerous and potential solutions must be 
discussed and adopted if any ground is to be made against the co-epidemic in 






The extent of HIV/TB co-infection, the fact that TB incidence is rising due to 
increased HIV prevalence, and the serious problems that HIV/TB create, call for 
a bold approach in tackling the co-epidemic. Dr Giddy comments on what she 
would like to see as a response to the problems of co-infection: “I would like to 
see a focus on new diagnostic tools and better treatment support.  Unlike HIV, 
we are all at risk for TB, especially people using public transport in winter, 
living in over-crowded conditions, or working in health care facilities.” (Giddy, 
2009) Four possibilities are briefly outlined in this section.  
 
The first of these is the implementation of earlier ARV treatment (perhaps even 
as soon as a person‟s positive status is known). In addition to the required 
expansion of ART in South Africa and many developing countries, there have 
been calls for earlier ARV treatment to be implemented as a way to reduce the 
spread of HIV, lengthen lives, and fight TB. It is argued that patients should 
start treatment before their CD4+ count falls below 350 cells per µL, and a 
recent study published in The Lancet shows that earlier treatment appears to 
keep patients healthier for longer (Lawn & Wood, 2009). Granich et al (2006) in 
a somewhat controversial paper have gone beyond this and suggested immediate 
ART as a preventative measure, given that HIV infectiousness falls close to zero 
once treatment has begun (Granich, Gilks, Dye, De Cock & Williams, 2008). 
Both of these measures would be helpful in the case of HIV and TB infection. 
Given that decreasing HIV prevalence seems to result in decreasing TB 
incidence, as argued earlier, if earlier ART can help to prevent the spread of 
HIV this will also impact positively on TB infection. Furthermore, healthier 
immune systems due to earlier treatment would also play a large role in 
preventing many HIV positive patients from contracting TB. The possibility of 
earlier treatment appears to be one which requires serious consideration as a 
solution and is being considered; it was proposed at the 2009 National AIDS 
conference in Cape Town. 
 
Secondly, a solution which would involve substantial investment and potentially 
take some time is the development of new TB diagnostic tests which are 
accurate, fast, and affordable for developing countries. It has been 20 years since 
the first HIV test was invented, and already there are inexpensive tests which 
have been developed and can diagnose a patient‟s HIV status with more than 
99% accuracy in less than 20 minutes (Achmat & Roberts, 2005; Centre for 
Disease Control and Prevention, 2006). No laboratories or skilled technicians 
are required. But there has not been similar investment and development into TB 
diagnostics, this has been pointed out already, and more funding for research 
into new TB tests is vital (while there have been recent developments in this 
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field nothing is available to the general public). With better diagnostics TB can 
be much more easily treated and overcome. In addition to new diagnostic tests, 
newer TB drugs aimed at shortening the treatment period of 6 months and 
decreasing the side-effects would also contribute to faster eradication of TB, 
lower default rates, and decreased development of MDR-TB.  
 
Thirdly, there is need for a greater level of integration between HIV and TB 
treatment, and an expansion of the current TB treatment framework. The extent 
of HIV/TB in South Africa must be recognised and all health facilities should 
strongly encourage both TB and HIV testing. The current strategy to treat TB is 
Directly Observed Treatment Short-course (DOTS), which requires TB patients 
to be observed while taking their treatment every weekday for six months 
(WHO, 2004). It also was intended to be used with patients who tested smear 
positive for TB, thus excluding many HIV positive patients. The framework 
should be broadened to include everyone on TB treatment. Greater integration 
would mean that patients are treated at the same health facility for both HIV and 
TB, thus ensuring that the treatment problems already mentioned are minimized. 
President Jacob Zuma in a national address on World Aids Day 2009 committed 
to a move in this direction where greater integration will be facilitated and co-
infected patients will be treated when their CD4 count is 350 or less. “All 
patients with both tuberculosis and HIV will get treatment with anti-retrovirals if 
their CD4 count is 350 or less. At present treatment is available when the CD4 
count is less than 200. TB and HIV/AIDS will now be treated under one roof”. 
(Zuma, 2009) 
 
Lastly, there is the possibility of using preventative TB therapy as a way to 
tackle the epidemic. People at high risk of developing TB, such as HIV positive 
individuals, may benefit significantly from Isoniazid Preventive Treatment (IPT) 
(WHO, 2004b). IPT is likely to provide protection against the risk of developing 
TB through two mechanisms; firstly, it decreases the risk of progression of 
infection, and secondly, it decreases the risk of reactivation of latent TB (WHO, 
2004b; WHO/UNAIDS, 1999). However, in populations with high TB 
prevalence, such as South Africa, the duration of benefit following completion 
of a 6-month course of IPT is limited to around 2.5 years (WHO, 2004b). The 
short duration is probably due to continued exposure to TB infection – also the 
period of protection depends on the length of preventive treatment (WHO, 
2004b). Taking IPT after a course of anti-TB therapy has been completed can 
also decrease the risk of TB recurrence in HIV-infected individuals, although it 
does not prolong survival (WHO, 2004b). The possibility of preventative 
treatment in HIV positive individuals could be examined in the South African 
case not only as an individual measure but also as an epidemiological measure. 
Individuals on IPT would reduce their risk of getting active TB, and in this way 
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the spread of TB could be contained as well. Given the high TB prevalence in 
South Africa and the risks faced by HIV positive individuals, IPT is a realistic 





This paper has examined the link between HIV and TB by investigating the 
theory behind it and analyzing the data. It is found that a change in HIV 
prevalence is associated with a change in TB incidence, in the same direction. 
The empirical link was established firstly through a comparison of South Africa 
and Uganda‟s infection rates over time where it was clear that the progression of 
TB followed that of HIV, and secondly by using a cross country regression of 
African countries in an attempt to isolate the effect of HIV on TB cases. The 
regression reported a large positive coefficient for “change in HIV prevalence” 
when controlling for other variables linked to TB incidence suggesting that a 
small change in the percentage of HIV prevalence is related to a significant 
change in the incidence of TB. This provides strong support to the medical 
arguments for a clear link between HIV and TB.  
 
The numerous problems created by the „terrible twins‟ were then examined in an 
effort to highlight the severity of HIV/TB co-infection. HIV positive individuals 
are at much higher risk of TB infection; the diagnosis of TB which is already 
challenging becomes even more so when a patient is HIV positive, and the TB 
progresses more quickly in an immuno-compromised body leading to many 
deaths. It is also increasingly difficult to measure South Africa‟s progress 
against TB since an overall TB cure rate does not exist; only patients diagnosed 
positively using the sputum smear test are included in the current cure rate 
statistics and high levels of co-infection impair the accuracy of this measure 
considerably.  
 
Finally, four interventions which would confront, and help to solve, the 
problems of co-infection were suggested. Firstly the implementation of earlier 
ARV treatment was discussed as a way to simultaneously combat the HIV 
epidemic and stop TB. The second intervention was the development of new TB 
diagnostic tests and the roll-out of new tests which have already been developed. 
Developing cheap and accurate TB testing technology may not be achievable in 
the short term but is a vital part of the fight against co-infection in the long run. 
Thirdly, an issue which has long been advocated by organizations such as the 
WHO, is the focus on treating HIV and TB together. Recognizing the difficulties 
posed by co-infection and the danger of TB in HIV positive patients this 
approach would broaden the current framework and allow for more 
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comprehensive treatment. This has recently been highlighted by President Jacob 
Zuma as one of South Africa‟s national healthcare goals. Fourthly there is 
opportunity to make use of preventative TB therapy for individuals. Such 
prophylactic treatment could play an important role in protecting HIV positive 





Change in Hiv Prev. GNI per capita Physicians per 1000 Urban Pop Life Expectancy Exp. on Health
Change in Hiv Prev. 1
GNI per capita 0.3432 1
Physicians per 1000 0.1606 0.2238 1
Urban Pop 0.0959 0.5711 0.2932 1
Life Expectancy -0.2943 0.0498 0.193 0.2857 1





Dependent Variable: Residual Squared Coefficient Std.Error t stat P>t
GNI per capita*Change in HIV Prev. 0.00533 0.00 2059 0.014
GNI per capita*Life Expectancy 0.00163 0.00 2.15 0.038
GNI per capita*Urban Pop -0.00014 0.00 -0.4 0.689
GNI per capita*GNI per capita 0.00000 0.00 1.04 0.303
Change in HIV Prev.*Life Expectancy -0.21183 0.92 -0.23 0.821
Change in HIV Prev.*Urban Pop -0.49642 0.41 -1.2 0.237
Change in Hiv Prev.*Change in HIV Prev. 1.06988 0.76 1.4 0.17
Life Expectancy*Urban Pop -0.22057 0.16 -1.36 0.181
Life Expectancy*Life Expectancy -0.01854 0.18 -0.1 0.921
Urban Pop*Urban Pop 0.06458 0.05 1.28 0.208
GNI per capita -0.10193 0.05 -2.24 0.031
Change in HIV Prev. -3.45888 39.57 -0.09 0.931
Urban Pop 7.69124 6.22 1.24 0.224
Life Expectancy 7.98172 16.74 0.48 0.637




White's Test for Heteroscedasticity
 
The White’s test statistic is N*R
2 =
 51*0.4736 = 24.15.Comparing this with the ² critical 
value, at the 5% level, of 31.3193 we do not reject the null hypothesis of no 
heteroscedasticity. On the basis of the White test we therefore conclude that there is no 
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